Cart
sales@molnova.com
CBP-IN-1
CAS No. 2222941-37-7
CBP-IN-1( —— )
Catalog No. M22843 CAS No. 2222941-37-7
CBP-IN-1 is a potent inhibitor of p300/CBP bromodomain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 528 | In Stock |
|
| 50MG | 755 | In Stock |
|
| 100MG | 1017 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCBP-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCBP-IN-1 is a potent inhibitor of p300/CBP bromodomain.
-
DescriptionCBP-IN-1 is a potent inhibitor of p300/CBP bromodomain.
-
In Vitro——
-
In VivoAnimal Model:Noncastrated male athymic nude mice Dosage:10-30 mg/kg Administration:Oral gavage; at 10 or 20 mg/kg daily (QD) or at 30 mg/kg every other day (QOD) for 28 days Result:Affected tumor growth at 10 mg/kg daily, 20 mg/kg daily, and 30 mg/kg every other day.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
Recptorp300/CBP
-
Research Areacancer
-
IndicationHaematological Malignancy|Acute Myeloid Leukemia|Non Hodgkin Lymphoma|Multiple Myeloma
Chemical Information
-
CAS Number2222941-37-7
-
Formula Weight534.6
-
Molecular FormulaC30H32F2N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (187.06 mM; Need ultrasonic)
-
SMILESO=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Neil Anthony Pegg, et al. Pharmaceutical compounds. WO2018073586A1.
molnova catalog
related products
-
2-methyl-2,3,4,5-tet...
2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.
-
PNZ5
PNZ5 is a potent and isoxazole-based pan-BET inhibitor, with high selectivity and potency similar to the well-established (+)-JQ1.
-
dCBP-1
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
